An Early Exploratory Clinical Study Protocol to Evaluate the Safety, Tolerability and Immunogenicity of KMV002 in Patients with Metastatic Androgen Pathway Modulator-Resistant Prostate Cancer (mAPMR) (ChiCTR) - Sep 16, 2026 - P=N/A | N=10 | Not yet recruiting | Sponsor: The West China Hospital of Sichuan University; The West China Hospital of Sichuan University
New trial • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor
|